Research has shown that immunotherapy pembrolizumab alone and in combination with chemotherapy is a more efficacious first line treatment for head and neck cancer that has returned than aggressive chemotherapy. The research was led by […]
AstraZeneca and Merck presented full results from the Phase 3 SOLO3 trial which evaluated LYNPARZA, compared to chemotherapy, for the treatment of platinum-sensitive relapsed patients with germline BRCA1/2-mutated (gBRCAm) advanced ovarian cancer, who have received […]
Swiss pharma giant Novartis’ Kisqali (ribociclib) succeeded in a phase 3 trial in combination with endocrine therapy as initial treatment in women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or […]
Lantheus Holdings has collaborated with NanoMab Technology to provide a novel biomarker for clinical development and management of immuno-oncology therapies. As part of strategic collaboration and licence agreement, the partnership will offer first broadly-available imaging […]
Iovance Biotherapeutics has announced plans to construct a commercial-scale production facility in Philadelphia, US. This 136,000ft2 plant will be used to develop tumour-infiltrating lymphocyte (TIL) cell therapy products for both clinical and commercial purposes. Iovance has signed […]